tipranavir
Also known as U-140690, TPV, 3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide
Tipranavir (TPV), or tipranavir disodium, is a nonpeptidic protease inhibitor (PI) manufactured by Boehringer Ingelheim under the trade name Aptivus . It is administered with ritonavir in combination therapy to treat HIV infection.
Chemical data
- Formula
- C31H33F3N2O5S
- Molecular weight
- 602.7 g/mol
- IUPAC name
- N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
- SMILES
- CCC[C@]1(CC(=C(C(=O)O1)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)O)CCC4=CC=CC=C4
- InChIKey
- SUJUHGSWHZTSEU-FYBSXPHGSA-N
- XLogP
- 7
- Polar surface area
- 114 Ų
- H-bond donors
- 2
- H-bond acceptors
- 10
- Formal charge
- 0
via PubChem
Research
512 papersArticle
2 sectionsContents
- References
- External links
{{Drugbox | Verifiedfields = changed | verifiedrevid = 470610685 | image = File:Tipranavir structure 2.svg | image_class = skin-invert-image | width = 275 | alt =
| pronounce = | tradename = Aptivus | Drugs.com = | MedlinePlus = a606009 | licence_EU = yes | DailyMedID = Tipranavir | licence_US = Tipranavir | pregnancy_AU = B3 | pregnancy_US = C | routes_of_administration = By mouth (soft capsules) | ATC_prefix = J05 | ATC_suffix = AE09 | ATC_supplemental =